1 day Ago By ABMN Staff
Novo Nordisk A/S ( NYSE:NVO – Get Free Report ) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect Novo Nordisk A/S to post earnings of $0.92 per share and revenue of $79.
17 billion for the quarter. Novo Nordisk A/S ( NYSE:NVO – Get Free Report ) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.
91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03.
Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%.
On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year. Novo Nordisk A/S Price Performance Shares of NYSE NVO opened at $65.12 on Wednesday.
Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.
The firm’s 50-day simple moving average is $72.84 and its 200 day simple moving average is $88.85.
The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.
62. The stock has a market cap of $292.23 billion, a P/E ratio of 19.
79, a P/E/G ratio of 0.90 and a beta of 0.61.
Novo Nordisk A/S Increases Dividend Wall Street Analyst Weigh In Several equities research analysts have commented on NVO shares. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th.
Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Dbs Bank cut shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th.
Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company.
According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $135.00.
Check Out Our Latest Analysis on NVO Hedge Funds Weigh In On Novo Nordisk A/S A hedge fund recently raised its stake in Novo Nordisk A/S stock. Revolve Wealth Partners LLC grew its holdings in Novo Nordisk A/S ( NYSE:NVO – Free Report ) by 8.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The firm owned 2,490 shares of the company’s stock after purchasing an additional 200 shares during the period. Revolve Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $214,000 as of its most recent SEC filing. 11.
54% of the stock is currently owned by institutional investors and hedge funds. About Novo Nordisk A/S ( Get Free Report ) Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
